ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1283

Frequency of Checking Creatine Kinase in Patients on Statins with Elevated Transaminase for Early Detection of Statin Induced Myopathy

ANJALI NIDHAAN, Andrei Hastings, david gonzalez, rajshri joshi, nathan gilbert and carolyn o'connor, Cleveland Clinic Akron General, Akron, OH

Meeting: ACR Convergence 2022

Keywords: Drug toxicity, Myopathies, Myositis, quality of care

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Measures and Measurement of Healthcare Quality Poster

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: Some of the most commonly reported side effects of statins (widely used lipid lowering agents) are muscle injury (incidence ranging from 0.1-20% based on type of muscle disorder) and hepatic dysfunction (incidence < 3%). Creatine kinase (CK) level in the blood is the most commonly used marker for assessing statin-induced myopathy. Apart from liver, skeletal muscles also produce transaminases. It is important to diagnose statin induced myopathy at an early stage in order to prevent complications such as rhabdomyolysis and immune mediated necrotizing myopathy. Continuing statins when there is muscle inflammation can lead to severe muscle weakness and disability. We explored how frequently clinicians check CK in patients with elevated transaminases to look for muscle injury.

Methods: This was a quality improvement project done through a retrospective chart review conducted in the various outpatient departments of Cleveland Clinic, OH and FL over a period of 5 years, from May 2017 to May 2022. We randomly selected 731 patients in outpatient setting who were taking statins and were diagnosed with elevated transaminases using ICD code: R74.01. Then we reviewed the records to ascertain if the subjects had a CK level checked within 1 month of diagnosis of elevated transaminases. Only total CK was considered; CK isoenzyme levels were not. Records were also reviewed for patients who did not have their CK level checked within 1 month of the diagnosis but had a gastroenterology consult placed within 2 months of the diagnosis. We labelled CK as elevated when they were flagged high per the laboratory cut off value (which varied based on laboratory, sex and age).

Results: Among 731 patients, only 169, or 23 %, had their CK checked within one month of the ICD10 diagnosis of elevated transaminase. Of these 169 subjects, 26 patients, or 15 %, had CK flagged as high based on laboratory cut offs. Among these 26 patients, 65 % had CK level >400 U/L and 19 % had CK level >1000 U/L. Hence, 3.5 % of the total study population had elevated CK levels.

562 patients, or 77 % did not have their CK checked. Of those who did not have CK checked, 20 patients, or 3.5 % had a gastroenterology consult placed within 2 months of the ICD diagnosis for further liver status workup.

Conclusion: We found that in our clinic, the majority of patients on statins with elevated transaminase levels did not have their CK checked in a timely fashion. Finding an elevated CK may prevent further unnecessary testing of liver status, reduce healthcare costs and allow for earlier treatment of statin- induced muscle damage. Efforts to train physicians to check muscle enzymes in patients on statins should be undertaken. Electronic Medical Record system(EMR) flagging of elevated transaminase levels prompting a CK check could be implemented.

Supporting image 1

TABLE 1 : PATIENT CHARCTERISTICS INCLUDED IN THE STUDY

Supporting image 2

FIGURE 1 : METHODS


Disclosures: A. NIDHAAN, None; A. Hastings, None; d. gonzalez, None; r. joshi, None; n. gilbert, None; c. o'connor, None.

To cite this abstract in AMA style:

NIDHAAN A, Hastings A, gonzalez d, joshi r, gilbert n, o'connor c. Frequency of Checking Creatine Kinase in Patients on Statins with Elevated Transaminase for Early Detection of Statin Induced Myopathy [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/frequency-of-checking-creatine-kinase-in-patients-on-statins-with-elevated-transaminase-for-early-detection-of-statin-induced-myopathy/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/frequency-of-checking-creatine-kinase-in-patients-on-statins-with-elevated-transaminase-for-early-detection-of-statin-induced-myopathy/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology